Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Director Ra Capital Management, L.P. Purchases 3,389,500 Shares
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Director Ra Capital Management, L.P. Purchases 3,389,500 Shares
Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Get Rating) Director Ra Capital Management, L.P. acquired 3,389,500 shares of the company's stock in a transaction dated Thursday, November 17th. The shares were bought at an average price of $12.50 per share, for a total transaction of $42,368,750.00. Following the purchase, the director now owns 4,384,206 shares in the company, valued at $54,802,575. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Acrivon Therapeutics Price Performance
Shares of Acrivon Therapeutics stock opened at $12.51 on Tuesday. Acrivon Therapeutics, Inc. has a 12-month low of $12.50 and a 12-month high of $20.70.
Get Acrivon Therapeutics alerts:About Acrivon Therapeutics
(Get Rating)
Acrivon Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops precision oncology medicines. The company's lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1/2 for use in the treatment of platinum-resistant ovarian cancer; endometrial and bladder cancer; and SCCs, including SCCHN, cervical, and anal cancer.See Also
- Get a free copy of the StockNews.com research report on Acrivon Therapeutics (ACRV)
- Three Ways To Win The Online Gambling Industry
- Santa Claus Rally? Here's What Needs to Happen
- Will the Return of Bob Iger Return the Magic to Disney Stock?
- Is Ardelyx is A Buy After Slip in Early 2022
- Is Tesla A Bargain Now As It Trades At Two-Year Lows?
Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Get Rating) Director Ra Capital Management, L.P. acquired 3,389,500 shares of the company's stock in a transaction dated Thursday, November 17th. The shares were bought at an average price of $12.50 per share, for a total transaction of $42,368,750.00. Following the purchase, the director now owns 4,384,206 shares in the company, valued at $54,802,575. The transaction was disclosed in a document filed with the SEC, which is available at this link.
阿克里馮治療有限公司(NASDAQ:ACRV-獲取評級)董事拉資本管理公司,L.P. 在 11 月 17 日(星期四)的一項交易中收購了 3,389,500 股該公司股票的股份。這些股份以每股 12.50 美元的平均價格買入,總交易額為 42,368,750.00 美元。購買後,董事現在擁有該公司 4,384,206 股股份,價值為 54,802,575 美元。該交易在向 SEC 提交的文件中披露,該文件可在以下網址獲得: 這個鏈接。
Acrivon Therapeutics Price Performance
acrivon 治療學價格表現
Shares of Acrivon Therapeutics stock opened at $12.51 on Tuesday. Acrivon Therapeutics, Inc. has a 12-month low of $12.50 and a 12-month high of $20.70.
艾克里芬治療學股票的股票在周二開盤 12.51 美元。阿克里馮治療學公司擁有 12 個月低點 12.50 美元和 12 個月高點 20.70 美元。
About Acrivon Therapeutics
關於阿克里馮治療
(Get Rating)
(取得評分)
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Acrivon Therapeutics (ACRV)
- Three Ways To Win The Online Gambling Industry
- Santa Claus Rally? Here's What Needs to Happen
- Will the Return of Bob Iger Return the Magic to Disney Stock?
- Is Ardelyx is A Buy After Slip in Early 2022
- Is Tesla A Bargain Now As It Trades At Two-Year Lows?
- 獲取有關艾克里芬治療學(ACRV)的研究報告的免費副本
- 贏得在線賭博行業的三種方法
- 聖誕老人拉力賽?這是需要發生的事情
- 鮑勃·伊格爾的歸來會將魔法歸還給迪士尼股票嗎?
- 阿德利克斯是 2022 年初滑倒後的買入嗎
- 特斯拉現在是否討價還價,因為它交易在兩年低點?
Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收有關 Arivon 治療學的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Acrivon 治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧